Posiflex Unveils Flagship Mozart BT Series POS Terminals
15.7.2024 10:02:00 EEST | Business Wire | Press release
Posiflex Technology Inc., a global leader in Point of Sale (POS) systems and Online to Offline (O2O) solutions, is pleased to announce its latest flagship POS terminal series – Mozart BT. The Mozart BT Series introduces beautiful modular monitor systems that integrate high-performance computing power, the latest operating system, and user-friendly ergonomic designs. With a high degree of modularity in construction and sleek elegance in appearance, the series conceals all cables and connectors, perfectly integrating the printer, providing a sense of space economy and aesthetics that enhances Posiflex's brand identity. The small and clean footprint of the Mozart BT Series allows seamless integration into various commercial spaces such as fashion boutiques, hospitality, convenience stores, food and beverage establishments, or multifunctional storefronts. Designed for versatility, it is an ideal solution for businesses requiring an additional display on the counter board for advertising playback, offering an elegant, beautiful, and useful POS terminal solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714496907/en/
Posiflex Mozart BT Series POS Terminals (Photo: Business Wire)
A Harmonious Work of Paper-Thin Elegance
Posiflex's Mozart BT Series, aptly named, strives to unite all its structural, functional, and aesthetic elements into a seamless harmony, reminiscent of a Symphony composition. Following the design principle of "less is more," the thinner display, host, and stand, along with narrower monitor bezels, not only reduce the system's size and weight but also enhance its functionality. Every curve and angle is meticulously crafted to convey a sense of elegance. Integrated and concealed designs ensure the elimination of exposed cables and connectors, presenting a clean and uncluttered aesthetic. The overall outcome is a sleek, harmonious, and elegant masterpiece.
Ripple Brand Identity
The ripple icon on the start button and thermal printer gives a sense of brand identity, symbolizing the continued vitality and the continuous quest for innovation and user benefit. The burgundy red on the sides of the stand suggests understated luxury and the deep, round taste associated with red wine.
Brilliant Modularity
Modular design has consistently been the pinnacle of innovation in Posiflex products, and the Mozart BT Series has elevated modularity to new heights. Each main component, from displays to the host and thermal printer, is independent, facilitating easy installation, removal for repair and maintenance, yet seamlessly integrates in function and structure when assembled into the system. The thermal printer is cleverly incorporated into the stand, becoming an integral part of the POS terminal base. Alternatively, it can function independently, showcasing a design that optimizes both space and functionality ingeniously.
User-Friendly Ergonomic Designs
The Mozart BT Series POS terminal incorporates ergonomic designs to optimize the user experience. Narrow bezels on the displays minimize interference with the user's view, directing attention to the screen. Moreover, the adjustable angles of the displays cater to the user's comfort and dynamic needs. Both main and secondary displays can be vertically oriented, aligning with current market trends. Additionally, all peripherals are positioned at the same level from the user's perspective, promoting heightened comfort.
State-of-the-Art Specifications
The Mozart BT Series POS Terminal stands out with a host of impressive features. It runs on the latest operating systems, including Android 13 with EDLA certified (GMS) or Windows 11 OS, available in both x86 and RISC variants. The terminal is powered by up to the latest 13th-generation Intel processor, ensuring top-notch performance. Users can choose between a 15" or 15.6" LCD display, notably the 15.6" main screen featuring oTP technology (typical 400 nits) for vibrant colors and high brightness. Plus, the terminal offers versatility with accessory and attachment choices, including the 3-in-1 side attachment for RFID/MSR/FPU, iButton, 2D BCR (discrete/side attached), and the detachable printer.
These features combine to provide a powerful and versatile electronic POS system with high-speed processing power and the ability to run the latest applications to meet the changing needs of the retail and hospitality industry.
About POSIFLEX Group
Posiflex Group is a global leading Commercial AIoT platform powered by smart Online-to-Offline (O2O) and Scenario-defined Embedded Appliance Solutions. Pillared by three brands, Posiflex Group consists of Posiflex as global top 5 brand in POS & Kiosk, Portwell as Embedded Foundry for AIoT Edge Compute, and KIOSK Information Systems (KIS) for managed self-service automation – together with a common mission to enable optimized productivity and superior customer journey across the connected world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714496907/en/
Contacts
Media:
Senior Marketing Manager, Jessie Hsu
Jessiehsu@posiflex.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom